Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VMD vs VTD in Relapsed/Refractory Multiple Myeloma
NCT00573391Phase 3
Key facts
- Status
- Terminated
- Start
- Aug 2006
- Primary completion
- Jul 2008
- Countries
- 1
- Sponsor
- University of Arkansas
- Modality
- Small Molecules, Modified Peptides
- Drugs
- bortezomib
- Conditions
- multiple myeloma (MM)
01
Overview
Phase 3, randomised, open-label trial of bortezomib in multiple myeloma (MM) (2 arms), sponsored by University of Arkansas. Primary endpoint: Participant Survival at 24 months. Started Aug 2006; status: terminated.
02
Design
2 arms- Study design
- RandomizedOpen-label
VTD Arm
Bortezomib + Thalidomide + Dexamethasone
VMD Arm
Bortezomib + Melphalan + Dexamethasone
03
Who it enrols
Patients with relapsed or progressive multiple myeloma after at least one autologous transplant, previously enrolled on UARK 98-026, with measurable disease and adequate organ function.
04
Endpoints
Primary
Participant Survival
Beyond the preview
Go deeper on NCT00573391.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00573391.